Genentech, Inc.South San Francisco, CA, United States (NYSE: DNA)

Tools:

What Additional Genentech Information Is Available From Hoover's?

Today's Special Offer

Company Description

"The few, the proud, the profitable" could be Genentech's motto. One of the world's most successful biotechs (in an industry full of...

Headquarters:

1 DNA Way
South San Francisco, CA 94080
United States  (Map)

Key Genentech Financials

Company Type Public - NYSE: DNA
Main Headquarters
Fiscal Year-End December
2007 Sales (mil.) $11,724.0
2007 Employees 11,174

Latest Genentech Jobs powered by Monster.com

  • Business Systems Analyst (FI-SAP)
  • Customer Relation Manager
  • Associate Director, Procurement

Rankings

  • #72 in FT Global 500

Competition

Competitive Landscape for Biotechnology Sector

Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...

Top Genentech Competitors

Genentech Executives sponsored by genius.com

Title Name & Bio Contact
Chairman, President, and CEO Arthur D. (Art) Levinson Network | E-mail
EVP and CFO David A. Ebersman Network | E-mail
SVP Development and Chief Medical Officer Hal V. Barron Network | E-mail
Are You Listed On Hoover's?
Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record.
Tools from our advertising partners:
 Resume Critique Start A Franchise  Easy Email Service

Latest Genentech Video

  • interviewee
    Genentech (DNA) Product Development President Dr. Susan Desmond-Hellman (5:02)
    06/04/07 9:45ET - CNBC's Mike Huckman interviews Dr. Desmond-Hellman about positive phase 3 trials of lung cancer drug Avastin.

Latest Industry Video

  • interviewee
    ASCO 2007 Preview (5:07)
    06/01/07 8:50AM ET - Wachovia Capital Markets Senior Biotech Analyst George Farmer and Miller Tabak Pharmaceutical Analyst Les Fundleyder discuss new drugs coming out at this year's conference.